Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 8, Issue 10, Pages 1239-1251
Publisher
Future Medicine Ltd
Online
2012-11-06
DOI
10.2217/fon.12.129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress
- (2012) Kevin S. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
- (2011) Janessa J. Laskin et al. Journal of Thoracic Oncology
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clusterin confers gmcitabine resistance in pancreatic cancer
- (2011) Qingfeng Chen et al. World Journal of Surgical Oncology
- Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD
- (2010) A. Zoubeidi et al. CANCER RESEARCH
- Overexpression of Clusterin in Ovarian Cancer is Correlated With Impaired Survival
- (2010) Guofen F. Yang et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Induction of Clusterin by AKT--Role in Cytoprotection against Docetaxel in Prostate Tumor Cells
- (2010) B. Zhong et al. MOLECULAR CANCER THERAPEUTICS
- Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays
- (2010) J. Bi et al. NEOPLASMA
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemosensitization of gemcitabine-resistant human bladder cancer cell line bothin vitroandin vivousing antisense oligonucleotide targeting the anti-apoptotic gene, clusterin
- (2009) Mototsugu Muramaki et al. BJU INTERNATIONAL
- Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
- (2009) S. Chia et al. CLINICAL CANCER RESEARCH
- Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer
- (2009) Li Wei et al. INTERNATIONAL JOURNAL OF CANCER
- Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis
- (2009) H Song et al. ONCOGENE
- Serum Level of Clusterin and Its Density in Men with Prostate Cancer as Novel Biomarkers Reflecting Disease Extension
- (2009) Hideaki Miyake et al. UROLOGY
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
- (2008) K. N. Chi et al. CLINICAL CANCER RESEARCH
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started